Nicole Lodowski | Graduate Center of the City University of New York (original) (raw)

Papers by Nicole Lodowski

Research paper thumbnail of Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma

Frontiers in immunology, Jun 10, 2024

Research paper thumbnail of Clinician Perspectives on Treatment-Decision in Triple-Class-Exposed Relapsed Refractory Multiple Myeloma in the United States: A Delphi-Based Research Study

Research paper thumbnail of Clinician and Administrator Perspectives on Chimeric Antigen Receptor (CAR) T-Cell Therapy Outpatient Administration in Relapsed or Refractory Multiple Myeloma (RRMM) in the United States (US): A Qualitative Study

Research paper thumbnail of Clinician and Administrator Perspectives on Chimeric Antigen Receptor (CAR) T-Cell Therapy Outpatient Administration in Relapsed or Refractory Multiple Myeloma (RRMM) in the United States

Transplantation and cellular therapy, Feb 1, 2024

Research paper thumbnail of PMU66 US Payer Decision Making Priorities: A Cohort Analysis across Eight Disease Categories

Research paper thumbnail of A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States

ClinicoEconomics and outcomes research : CEOR, 2018

The aim of this study was to conduct a systematic literature review on the burden of schizophreni... more The aim of this study was to conduct a systematic literature review on the burden of schizophrenia in privately insured US patients. A systematic literature review of English language peer-reviewed journal articles of observational studies published from 2006 to 2016 was conducted using EMBASE/MEDLINE databases. Abstracts covering substantial numbers of patients with schizophrenia or schizoaffective disorder (i.e., N ≥ 100) were included for full-text review. Articles that did not clearly specify private insurance types were excluded. A total of 25 studies were reviewed; 10 included only privately insured patients; and 15 included a mix of different types of insurance. The review of the clinical burden of schizophrenia revealed the following: compared to patients with no mental disorders, those with schizophrenia had significantly increased odds of systemic disorders and both alcohol and substance abuse. Antipsychotic (AP) adherence was low, ranging from 31.5% to 68.7%. The medicati...

Research paper thumbnail of Clinician and administrator perspectives on outpatient administration of ciltacabtagene autoleucel in relapsed or refractory multiple myeloma

Frontiers in immunology, Jun 10, 2024

Research paper thumbnail of Clinician Perspectives on Treatment-Decision in Triple-Class-Exposed Relapsed Refractory Multiple Myeloma in the United States: A Delphi-Based Research Study

Research paper thumbnail of Clinician and Administrator Perspectives on Chimeric Antigen Receptor (CAR) T-Cell Therapy Outpatient Administration in Relapsed or Refractory Multiple Myeloma (RRMM) in the United States (US): A Qualitative Study

Research paper thumbnail of Clinician and Administrator Perspectives on Chimeric Antigen Receptor (CAR) T-Cell Therapy Outpatient Administration in Relapsed or Refractory Multiple Myeloma (RRMM) in the United States

Transplantation and cellular therapy, Feb 1, 2024

Research paper thumbnail of PMU66 US Payer Decision Making Priorities: A Cohort Analysis across Eight Disease Categories

Research paper thumbnail of A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States

ClinicoEconomics and outcomes research : CEOR, 2018

The aim of this study was to conduct a systematic literature review on the burden of schizophreni... more The aim of this study was to conduct a systematic literature review on the burden of schizophrenia in privately insured US patients. A systematic literature review of English language peer-reviewed journal articles of observational studies published from 2006 to 2016 was conducted using EMBASE/MEDLINE databases. Abstracts covering substantial numbers of patients with schizophrenia or schizoaffective disorder (i.e., N ≥ 100) were included for full-text review. Articles that did not clearly specify private insurance types were excluded. A total of 25 studies were reviewed; 10 included only privately insured patients; and 15 included a mix of different types of insurance. The review of the clinical burden of schizophrenia revealed the following: compared to patients with no mental disorders, those with schizophrenia had significantly increased odds of systemic disorders and both alcohol and substance abuse. Antipsychotic (AP) adherence was low, ranging from 31.5% to 68.7%. The medicati...